Share on :

Asset Summary

Weekly Performance Report for AMGN ETF: Week 51, 2024

Summary: The Weekly started with AMGN ETF opening at $270.62 and closing at $263.38. The ETF showed weakness throughout the Weekly, with the highest price observed at $272.69 and the lowest at $253.3. The underlying asset had a trading range of $19.39 Overall, it was a negative trading Weekly for AMGN ETF, reflecting investor pessimism and market activity.

Change in Closing Price: There was a net decrease of $-7.24 or -2.68% in the closing price from the opening to the closing price over the Weekly.

Volume Analysis: Trading volume for AMGN ETF was 30,961,378 units during Week 51, indicating active market participation and investor interest.

Opening Price: The Weekly started at $270.62.

Highest Price: The highest price observed during the Weekly was $272.69.

Lowest Price: The lowest price observed during the Weekly was $253.3.

Closing Price: The Weekly ended at $263.38.

Asset Performance Metrics and Risk Characteristics:

Understanding asset performance is crucial for evaluating investment quality and making informed decisions. Metrics like trailing return and drawdown provide insights into how an asset has performed over time, its volatility, and the efficiency of its returns relative to risk. Performance indicators help assess the stability, risk, and reward of an investment, allowing investors and portfolio managers to make comparisons and strategize accordingly.

Asset Technical Analysis

Technical analysis involves evaluating an asset's price and volume data to forecast future movements and make informed trading decisions. By using various technical indicators and chart patterns, investors can gain insights into market trends, price momentum, and potential turning points. This section delves into essential technical metrics, including moving averages, pivot points, and other indicators that provide a snapshot of an asset's current technical stance. Analyzing these indicators helps investors identify entry and exit points, assess market sentiment, and refine their trading strategies. Explore the following technical analysis data to understand the asset's performance dynamics and make better-informed decisions.

Moving Averages

Moving Averages are commonly used to smooth out price data and identify trends over a specific period. Here’s a summary of the latest moving averages for various periods:

  • SMA (Simple Moving Average): Reflects the average price over a specific number of periods.
  • EMA (Exponential Moving Average): Gives more weight to recent prices, making it more responsive to new information.
  • WMA (Weighted Moving Average): Assigns a weight to each price, emphasizing more recent prices.
  • WEMA (Weighted Exponential Moving Average): Combines elements of both WMA and EMA for a more responsive moving average.

Advance Your AMGN Trading Now

Unlock the full potential of AMGN with Rank My Trade Online’s cutting-edge automated trading system. Our platform provides precise price action analysis, advanced technical indicators, and powerful quantitative algorithms. Enhance your market performance today and transform your trading experience today!

Get Advanced Analysis Now

Frequently Asked Questions

Amgen’s key products include therapies for cancer, kidney disease, rheumatoid arthritis, and other serious medical conditions, such as Neulasta and Enbrel.

Risks include regulatory challenges, competition from generic drugs, and the volatility associated with biotechnology stocks.

Amgen reports its financial results on a quarterly and annual basis, offering insights into its earnings and business operations.

Amgen develops innovative medicines that address serious diseases, improving patient outcomes and enhancing the quality of life for patients globally.

Amgen is headquartered in Thousand Oaks, California, USA.

Amgen is recognized for its robust research pipeline, innovative therapies, and commitment to quality in biopharmaceuticals.

Investing in AMGN may be attractive if you believe in the growth potential of the biotechnology sector, but potential investors should conduct thorough research.

Historically, AMGN has shown strong performance and resilience, reflecting the growth trends in the biotechnology sector.

Amgen generates revenue primarily through the sale of its biologic drugs and therapies, as well as licensing agreements and partnerships with other companies.

Yes, AMGN can typically be included in retirement accounts such as IRAs or 401(k)s, depending on your brokerage options.

Supercharge Your AMGN Trading Now

Transform your approach to trading with RankMyTrade. Our automated system offers detailed metrics and technical analysis for AMGN, tailored to enhance your trading performance. Transform your trading strategy now and elevate your strategy today!

Disclaimers

The information displayed on this site is sourced from third-party providers and is believed to be reliable. RankMyTrade (RMT) has not independently verified this data and does not guarantee its accuracy. The information and calculations provided by RankMyTrade are for educational and informational purposes only and should not be construed as financial or investment advice.

With any investment, your capital is at risk. The value of your portfolio go down as well as up. Past performance is no guarantee of future results. By using this website, you accept our Terms of Service, Privacy Policy, and Payment Agreement.

Market data is provided in near real-time when available, but we do not guarantee its accuracy or timeliness.

Securities products are: Not FDIC insured · Not bank guaranteed · May lose value

Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind. Unless otherwise noted, RankMyTrade and its affiliates are not partners, affiliates, or licensees of these companies.

Supported Assets & ETFs